From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia
Therapeutic Advances in Respiratory Disease · 2025
DOI: 10.1177/17534666251332085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Saibin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Jinhua, Zhejiang Province, China. Hauptthemen laut MEDLINE: Immunocompromised Host, Community-Acquired Infections, Glucocorticoids, Pneumonia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Science and Technology Major Project of Jinhua City.
Abstract (Originalsprache)
Background
Chronic glucocorticoid therapy is known to heighten the risk of secondary pulmonary infections. However, the impact of cumulative glucocorticoid dosage (CGD) on mortality risk in patients who develop community-acquired pneumonia (CAP) while undergoing glucocorticoid therapy remains inadequately explored.
Objectives
This study aims to clarify the relationship between CGD and mortality outcomes in immunocompromised patients with CAP.
Design
This study is a retrospective cohort analysis utilizing data from the DRYAD database.
Methods
We examined data from 561 patients diagnosed with CAP who had received either oral or intravenous glucocorticoids prior to their CAP diagnosis. To evaluate the effect of CGD on mortality risk, we employed piecewise linear regression and Cox regression analyses, adjusting for relevant confounders.
Results
Among the study population, the median CGD was 4 g of methylprednisolone (interquartile range 2.16–8.80 g). The 30-, 60-, and 90-day mortality rates were 22.28%, 25.13%, and 25.49%, respectively. Piecewise linear regression analysis revealed a nonlinear relationship between methylprednisolone dose and mortality risk, indicating a threshold effect at a methylprednisolone level of 20 g. In addition, Cox regression analysis showed a significantly higher mortality risk in patients with CGD exceeding 40 g of methylprednisolone compared to those with CGD between 20 and 40 g, after adjusting for potential confounding factors (adjusted HR 5.16, 95% CI: 1.16–22.99, p < 0.05).
Conclusion
CAP occurring in close proximity to recent high doses of steroids is associated with pathogens typically seen in immunocompromised hosts and is linked to higher mortality compared to usual CAP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, Jinhua, Zhejiang Province, China.
- School of Medicine, Shaoxing University, Shaoxing, Zhejiang Province, China.
- Department of Medical Records Quality Management, Jinhua Municipal Central Hospital, Jinhua, Zhejiang Province, China.
- Department of Pulmonary and Critical Care Medicine, Jinhua Municipal Central Hospital, No. 365, East Renmin Road, Jinhua 321000, Zhejiang Province, China.
ORCID-Profile: Saibin Wang
Förderung
- the Science and Technology Major Project of Jinhua City
Zitieren
APA
Wang, S., Ye, Q., & Sheng, Y. (2025). From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251332085
Vancouver
Wang S, Ye Q, Sheng Y. From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251332085
BibTeX
@article{Wang2025,
author = {Wang, Saibin and Ye, Qian and Sheng, Yijun},
title = {From treatment to threat: the fatal impact of cumulative glucocorticoid dosage on outcomes in immunocompromised patients with community-acquired pneumonia},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
doi = {10.1177/17534666251332085}
}
EUVIMED